graphic access to TB diagnostic and treatment facilities might infl uence pre-treatment loss to follow-up rates. Such information would be useful to assess and improve programme performance. Fiji is a Pacifi c Island country that has been implementing the DOTS strategy since 1997. 9 There are an estimated 23 TB cases per 100 000 population, of which ~10/100 000 are smear-positive PTB cases.
G
lobally, under the National Tuberculosis Programme (NTP), a patient who does not appear in the tuberculosis (TB) treatment register after having been diagnosed with sputum smear-positive pulmonary TB (PTB), and thus is not initiated on anti-tuberculosis treatment, is known as a 'pre-treatment loss to followup'. 1 These patients were previously referred to as 'initial defaulters'. 2 From the perspective of the TB services, 'pre-treatment loss to follow-up' is important for two main reasons. First, untreated smear-positive PTB patients are infectious and may transmit TB to others in the community, constituting an important public health risk. Second, if and when such patients are identifi ed in the health services, their illness is likely to have progressed and this can negatively infl uence their treatment outcome.
Previous studies in Africa and Asia have reported pre-treatment loss to follow-up rates of 5% to 25%, and various associated factors have been identifi ed. [3] [4] [5] [6] [7] [8] In the Pacifi c Islands, there is no published information about the extent of this problem, nor whether p atients' socio-demographic characteristics and geo- TB cases are then supposed to be referred to one of the two TB treatment centres, recorded in the TB treatment register and started on anti-tuberculosis treatment.
Study population and identification of pre-treatment loss to follow-up
All patients found to be sputum smear-positive in the sputum laboratory registers of the four laboratories from 2001 to 2010 were included in the study. The TB treatment registers were carefully reconciled with the laboratory registers. A patient who was sputumpositive on the laboratory register but not found on the TB treatment register was declared as 'pre-treatment loss to follow-up'.
Data and statistical analysis
The following data were collected from the laboratory registers: year, socio-demographic characteristics (including name) and geographic residence. Data were entered into EpiData (EpiData Association, Odense, Denmark) and cross-checked for consistency; discrepancies were corrected by referring to the original records. Risk of pre-treatment loss to follow-up was measured using crude odds ratios (ORs) and their 95% confi dence intervals (CIs). The level of signifi cance was set at 5%.
Ethics approval
Ethical approval was obtained from the Fiji National Research Ethics Committee and the Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease, Paris, France.
RESULTS
During the period 2001-2010, a total of 690 sputum smearpositive TB patients were diagnosed in the laboratory, of whom 579 (84%) were started on anti-tuberculosis treatment-an overall pre-treatment loss to follow-up of 111 (16%). The trend in pretreatment loss to follow-up over the 10-year period is shown in Table 1 . Peak loss-to-follow-up rates were seen in 2003, 2004 and 2010. Patients lost to follow-up were all aged ⩾15 years ( Table 2) . From the Western Division of Fiji, 33% of sputum-positive patients were declared pre-treatment loss to follow-up and had over fi ve times the risk of such an outcome compared to the Central Division (OR 5.2, 95%CI 3.1-8.9, P < 0.0001).
FIGURE Map of Fiji showing the geographic divisions.
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DISCUSSION
This fi rst study from the Pacifi c Islands to assess pre-treatment loss to follow-up rates over a decade shows that about two in 10 individuals with infectious TB were not placed on antit uberculosis treatment. The Western Division of Fiji had the highest rates. The strengths of this study are that we included country-wide data that come from the routine programme setting and are thus likely to refl ect the operational reality on the ground, and data were rigorously cross-checked and validated for accuracy. We also adhered to STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines on reporting of observational studies. 10 The limitations are that we examined risk of loss to follow-up using a limited number of variables and we did not trace patients to verify whether they had started anti-tuberculosis treatment elsewhere. However, in Fiji, as anti-tuberculosis treatment is only available at centres included in this study, it is unlikely that patients could have accessed care elsewhere. Our results are thus likely to be realistic.
The programme implications of these fi ndings are two fold. First, a considerable proportion of infectious TB cases are not being placed on anti-tuberculosis treatment, and this constitutes a public health risk. Second, cohort reporting of programme outcomes that excludes this group will portray an incorrect picture of programme success, and this is a shortcoming.
We propose a number of ways to correct the current situation. First, the TB laboratory register should include the detailed address and telephone numbers of patients with TB to allow tracing and follow-up. Second, the laboratory and treatment registers should be reconciled on a regular, scheduled basis (e.g., every 2 weeks) to allow early detection of pre-treatment loss to followup. To facilitate this process, the laboratory register number should also be entered into the TB patient treatment register and vice versa. Third, quarterly TB reporting should include the number and proportion of pre-treatment loss to follow-up patients. This will allow the NTP to be vigilant and to act in time. Finally, there is a need for specifi c investigations in the Western Division of Fiji to evaluate the reasons for the higher rates of pre-treatment loss to follow-up here.
In conclusion, this study has identifi ed an important shortcoming in programme linkage, communication and feedback between TB diagnostic and treatment services leading to high pretreatment loss to follow-up rates. This negatively infl uences TB services, and urgent steps are being taken to rectify this situation. ; P < 0,0001). Conclusión: En el presente estudio se pusieron en evidencia graves deficiencias al comparar los datos del programa, la comunicación y la retroalimentación entre los servicios de diagnóstico y tratamiento de la TB, lo cual da origen a altas tasas de pérdida temprana de pacientes durante el seguimiento, antes comenzar el tratamiento. Esta situación tiene repercusiones negativas en el desempeño de los servicios de atención de la TB. En el artículo se analizan los mecanismos que permitirían rectificar estas insuficiencias.
